Growth factor signalling in endocrine and anti-growth factor resistant breast cancer

Rev Endocr Metab Disord. 2007 Sep;8(3):241-53. doi: 10.1007/s11154-007-9033-5.


Growth factors provide powerful mitogenic and survival signals to breast cancer cells and it is therefore not surprising that they are able to subvert inhibitory responses to anti-hormonal drugs. In this review we discuss several mechanisms by which this may be achieved and expand our observations to encompass recently emerging anti-growth factor treatments. The information presented is underpinned by inhibitor studies that show the targeting of such mechanisms in advance of anti-hormone or anti-growth factor resistance development is able to substantially delay this event, thus pointing the way forward to intelligent combination therapies relevant to the future management of breast cancer.

Publication types

  • Review

MeSH terms

  • Breast Neoplasms / physiopathology*
  • ErbB Receptors / physiology
  • Female
  • Humans
  • Intercellular Signaling Peptides and Proteins / physiology*
  • Receptors, Estrogen / physiology
  • Signal Transduction / physiology*


  • Intercellular Signaling Peptides and Proteins
  • Receptors, Estrogen
  • ErbB Receptors